NIQ Global Intelligence plcBroad Q2 earnings beat and raised full-year outlook.
U.S. stock futures were little changed on Tuesday, as fading hopes for a deal to reopen the Strait of Hormuz kept oil prices elevated, while investors looked ahead to key U.S. inflation data for fresh clues on the Federal Reserve's interest rate path. Riot Platforms shares surged 18.3% in premarket trading after the company landed a $9.1 billion, 20-year AI data center contract with Anthropic, marking one of the largest deals yet to link the cryptocurrency mining industry with the rapidly expanding AI infrastructure market. NIQ Global Intelligence shares surged 15.2% after delivering a broad second-quarter earnings beat and raising its full-year outlook, with adjusted EPS of $0.27 versus a $0.21 consensus and revenue of $1.12 billion edging past expectations of $1.11 billion. On Holding shares fell 15.2% after reporting second-quarter net sales of CHF 850.3 million, below the roughly CHF 881 million analysts had expected, as management pointed to a more difficult consumer environment and higher U.S. tariff costs. Rocket Lab shares dropped 9% despite record second-quarter revenue of $234 million, as third-quarter GAAP gross margin guidance of 29% to 31% came in well below the Street's estimate of about 37.6%. Hims & Hers Health shares fell nearly 7% even after better-than-expected revenue and a raised full-year forecast, as investors focused on profitability pressures from expansion into branded GLP-1 weight-loss drugs and international markets.
NIQ Global Intelligence plcBroad Q2 earnings beat and raised full-year outlook.
Cipher Mining Inc
Hut 8 Corp. Common Stock
Riot Platforms, Inc.Landed $9.1 billion AI data center contract with Anthropic.
CleanSpark Inc
Terawulf Inc
On Holding LtdQ2 sales missed expectations due to difficult consumer environment and higher U.S. tariff costs.
Rocket Lab USA Inc.Q3 gross margin guidance well below Street estimate despite record revenue.
Hims Hers Health IncProfitability pressures from expansion into branded GLP-1 drugs and international markets despite revenue beat.
CEVA Inc
Ceragon Networks Ltd
Evercore Partners Inc